In addition, a bispecific antibody targeting PD-1 and LAG-3 (RO7247669) is currently being evaluated in a clinical trial (NCT04140500) for its preliminary antitumor activity in NSCLC patients who have previously received PD-1/L1 inhibitors. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.